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ABSTRACT  42 
Changes in the balance between glutamate (Glu) release and uptake may stimulate synaptic 43 
reorganization and even synapse loss. In the case of neurodegeneration, a mismatch between 44 
astroglial Glu uptake and presynaptic Glu release could be detected if both parameters were 45 
assessed independently and at a single synapse level.  This has now become possible due to a 46 
new imaging assay with the genetically encoded ultrafast Glu sensor iGluu. We report 47 
findings from individual corticostriatal synapses in acute slices prepared from mice of either 48 
sex aged >1 year. Contrasting patterns of short-term plasticity and a size criterion identified 2 49 
classes of terminals, presumably corresponding to the previously defined IT and PT synapses. 50 
The latter exhibited a higher degree of frequency potentiation/residual Glu accumulation and 51 
were selected for our first iGluu single synapse study in Q175 mice, a model of Huntington’s 52 
disease (HD). In HD mice, the time constant of perisynaptic [Glu] decay (TauD, as indicator 53 
of uptake) and the peak iGluu amplitude (as indicator of release) were prolonged and reduced, 54 
respectively. Treatment of WT preparations with the astrocytic Glu uptake blocker TFB-55 
TBOA (100 nM) mimicked the TauD changes in homozygotes (HOM). Considering the 56 
largest TauD values encountered in WT, about 40% of PT terminals tested in Q175 57 
heterozygotes (HET) can be classified as dysfunctional. Moreover, HD but not WT synapses 58 
exhibited a positive correlation between TauD and the peak amplitude of iGluu. Finally, 59 
EAAT2 immunoreactivity was reduced next to corticostriatal terminals. Thus, astrocytic Glu 60 
transport remains a promising target for therapeutic intervention.   61 
 62 
SIGNIFICANCE STATEMENT  63 
Alterations in astrocytic Glu uptake can play a role in synaptic plasticity and 64 
neurodegeneration. Until now, sensitivity of synaptic responses to pharmacological transport 65 
block and the resulting activation of NMDA receptors were regarded as reliable evidence for 66 
a mismatch between synaptic uptake and release. But the latter parameters are interdependent. 67 
Using a new genetically encoded sensor to monitor [Glu] at individual corticostriatal synapses 68 
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we can now quantify the time constant of perisynaptic [Glu] decay (as indicator of uptake) 69 
and the maximal [Glu] elevation next to the active zone (as indicator of Glu release). The 70 
results provide a positive answer to the hitherto unresolved question whether 71 
neurodegeneration (e.g. Huntington’s disease) associates with a glutamate uptake deficit at 72 
tripartite excitatory synapses. 73 
 74 
INTRODUCTION  75 
A low level of steady state glutamate concentration [Glu] is an important prerequisite for high 76 
spatial and temporal discrimination of afferent signals. Electrogenic transport of Glu from the 77 
environment of active synaptic terminals into astroglial cells secures resting [Glu] levels 78 
below 100 nm (Bergles et al., 1999; Marcaggi and Attwell, 2004; Tzingounis and Wadiche, 79 
2007; Nedergaard and Verkhratsky, 2012; Papouin et al., 2017; Rose et al., 2018). Compared 80 
to other synaptically enriched proteins, including the AMPA receptors, excitatory amino acid 81 
transport proteins (EAAT1 and EAAT2, GLAST and GLT1 in rodents) are very abundant 82 
(Lehre and Danbolt, 1998; Marcaggi and Attwell, 2004; Cahoy et al., 2008) forming clusters 83 
on the perisynaptic astroglial processes (PAPs) next to the sites of transmitter release (Lehre 84 
and Danbolt, 1998; Melone et al., 2011). However, the proximity between the sites of 85 
synaptic Glu release and astrocytic uptake could vary according to the type of synapse or the 86 
functional state of the involved cells (Octeau et al., 2018).   87 
 88 
Insufficient expression/activity of EAAT2 is considered among the mechanisms promoting 89 
excitotoxic damage and neurodegeneration (Pekny et al., 2016; Verkhratsky et al., 2016). As 90 
for HD, there is full agreement that transcription of  the EAAT2 encoding gene SLC1A2 and 91 
tissue uptake of radio-labelled EAAT2 substrates are reduced in comparison with healthy 92 
controls (Lievens et al., 2001; Behrens et al., 2002; Shin et al., 2005; Miller et al., 2008; 93 
Bradford et al., 2009; Faideau et al., 2010; Huang et al., 2010; Menalled et al., 2012; Grewer 94 
et al., 2014; Meunier et al., 2016). Records from striatal astrocytes (Dvorzhak et al., 2016) 95 
suggested a 20-30% decrease of the glutamate uptake activity in two mouse models of HD, 96 
R6/2 and Q175. Yet some caution is needed as it has remained unclear whether or not the 97 
well-documented reduction of astrocytic Glu transport is to be regarded as a primary cause of 98 
synapse dysfunction/loss, or merely as an epiphenomenon reflecting glial adjustment to the 99 
massive pruning of  glutamatergic terminals for other yet unknown reasons (Deng et al., 2013; 100 
Rothe et al., 2015). As synapse degeneration is likely to progress in a rather asynchronous 101 
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manner resulting in a co-existence of dysfunctional and more or less healthy terminals, a 102 
satisfying answer regarding the adequate performance of astrocytic glutamate uptake in HD 103 
can only be obtained at the single synapse level and under consideration of the individual 104 
uptake/release relationships (Barbour, 2001; Nahir and Jahr, 2013; Jensen et al., 2017; 105 
Reynolds et al., 2018).  106 
 107 
The striatum as the most affected brain structure in HD (Khakh et al., 2017) is well suited for 108 
selective activation of glutamatergic synapses as it lacks intrinsic glutamatergic neurons. 109 
Glutamatergic afferents originate in the medial thalamus and the cerebral cortex (see (Reiner 110 
and Deng, 2018) for more). Corticostriatal connections are formed by at least two distinct 111 
populations of pyramidal neurons, localized in layers 2/3 and 5. The axons originating in layer 112 
2/3 establish bilateral intra-telencephalic (IT) connections, while layer 5 axons enter the 113 
pyramidal tract (PT) and lack telencephalic collaterals to the contralateral side. Elegant 114 
electrophysiology (Kincaid et al., 1998) and electron microscopy studies (Reiner et al., 2010) 115 
discovered a number of differences between PT and IT afferents and their synaptic 116 
varicosities. In view of this diversity one could expect some type-dependent differences in the 117 
release characteristics and, accordingly, differential sensitivity to factors that may cause an 118 
uptake/release imbalance.  119 
 120 
Here we report the results of the first single synapse experiments in striatal slices of adult 121 
mice performed with the ultrafast Glu sensor iGluu (Helassa et al., 2018). We have addressed 122 
three main questions: 1) How does activation frequency affect the Glu release and uptake at 123 
corticostriatal terminals? 2) Does HD produce an uptake/release mismatch? 3) If so, could the 124 
indicators of uptake and/or release be used to identify dysfunctional synapses?  125 
 126 
MATERIALS AND  METHODS  127 
Animals. The work described here has been carried out in accordance with the EU Directive 128 
2010/63/EU for animal experiments and was registered at the Berlin Office of Health 129 
Protection and Technical Safety (G0233/14 and G0218/17). Z-Q175-KI mice were obtained 130 
from CHDI ("Cure Huntington's Disease Initiative", see stock # 027410 of the Jackson 131 
Laboratory, Bar Harbor, USA). The number of CAG repeats ranged from 182 to 193. The 132 
recordings were performed in animals of either sex at an age of 51 to 76 weeks.  133 
 134 
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Plasmids. pAAV-CaMKIIa-ChR2(H134R)-EYFP and pAAV-CaMKIIa-135 
hChR2(E123T/T159C)-EYFP (Addgene, Watertown, USA #26969 and #35511) were gifts 136 
from Karl Deisseroth. To create pAAV-CaMKIIa-iGluu (Addgene #75443), the iGluu gene 137 
was amplified by PCR from pCI-syn-iGluu (Addgene #106122) using Phusion polymerase 138 
(forward 5’-CATCAGGATCCATGGAGACAGACACACTCC-3’, reverse 5’-139 
GTATGGAATTCCTAACGTGGCTTCTTCTGCC-3’) and cloned into pAAV-CaMKIIa-140 
hChR2(H134R)-EYFP by restriction-ligation using BamHI/EcoRI restriction enzymes (NEB) 141 
and T4 DNA ligase (NEB). AAV9-CaMKIIa.iGluu.WPRE-hGH and AAV9-142 
CaMKIIa.hChR2(E123T/T159C)-EYFP.hGH were packaged at University of Pennsylvania 143 
Vector Core (Penn Vector Core). 144 
 145 
Drugs and antibodies. All substances were obtained from Sigma Aldrich/Merck, Taufkirchen, 146 
Germany, except TTX (Abcam, Cambridge, UK) and TFB-TBOA (Tocris, Bristol, UK). The 147 
primary antibodies included those to vGluT1 (1:1000, guinea pig, Synaptic Systems #135304) 148 
and EAAT2 (1:2000, rabbit, Abcam #ab41621). Secondary antibodies against guinea pig and 149 
rabbit, were conjugated to Alexa 488 or 555 and obtained from Life Technologies (#A-11073, 150 
#A-21429, respectively).  151 
 152 
Injections and brain slice preparation. The animals were anesthetized by intraperitoneal 153 
injection of a mixture containing 87.5 mg/kg ketamine and 12.5 mg/kg xylasine before 154 
receiving 4 intracortical injections of AAV9-CamKII.iGluu.WPRE-hGH (7.34*10
13gcC/ml - 155 
0.3 μl) or 1 intracortical injection of AAV9-CaMKIIa.hChR2(E123T/T159C)-EYFP.hGH 156 
(6.28*1012 gc/ml - 1 μl) at the following coordinates with respect to bregma (mm): anterior 157 
1.5, lateral 1.56, 1.8, 2.04, 2.28 and ventral 1.7.  About 3 weeks (ChR2) or 6 weeks (iGluu) 158 
later the animals were anesthetized with isoflurane, transcardially perfused with cooled 159 
aerated saline containing (in mM): N-methylglucamine chloride (NMDG) 92, KCl 2.5, 160 
NaH2PO4 1.25, NaHCO3 25, glucose 20, CaCl2 0.5, MgCl2 10, sodium pyruvate 3, and 161 
sodium ascorbate 5 (pH 7.35, 303 mosmol/l). After decapitation and removal of the brains, 162 
parasagittal (10 deg off) sections (300 μm) containing the striatum were prepared as 163 
previously described (Dvorzhak et al., 2016). The slices were kept in artificial cerebrospinal 164 
fluid (ACSF) containing (in mM): NaCl 125, KCl 3, NaH2PO4 1.25, NaHCO3 25, CaCl2 2, 165 
MgCl2 1, glucose 10 (pH 7.3, 303 mosmol/l), supplemented with (in mM): sodium pyruvate 166 
0.5, sodium ascorbate 2.8 and glutathione 0.005. These perfusion and recovery solutions 167 
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preserved the astrocytes better than physiological ACSF, sucrose- or choline-containing 168 
solutions, the criteria being resting membrane potential at break-in (WT: <=-85 mV). Q175 169 
HOM were also injected with CEF (5 consecutive days before testing, 200 mg/kg i.p.) or the 170 
respective control solution (physiological saline).  171 
 172 
Quantification of synaptic [Glu] elevations with iGluu. The biophysical characteristics of the 173 
new ultrafast Glu sensor (iGluu) were already described (Helassa et al., 2018). Briefly, 174 
responses to saturating Glu concentration (10 mM) were recorded in transduced HEK293T 175 
cells. An iGluu off rate of 2.1 ms was determined using recombinant purified protein and 176 
stopped flow fluorimetry. For the imaging of synaptically released Glu, slices were 177 
submerged into a perfusion chamber with a constant flow of oxygenated ACSF at a rate of 1-178 
2 ml/min. Temperature during the recordings was maintained at 26 - 27 °C. In non-stimulated 179 
acute slices from >1 year old mice corticostriatal varicosities were visualized in the dorsal 180 
striatum using a Zeiss W Plan-Apochromat 63x /NA 1.0 water immersion objective and brief 181 
(180 ms) discontinuous exposure to a 473 nm laser beam focused to a circular area of ~4.5 182 
μm in diameter centered to a presynaptic varicosity. The distance to the nearest other 183 
fluorescent varicosity was typically 3 to 5 μm. The size of non-stimulated boutons was 184 
derived from the area of supra-threshold pixels, the threshold being defined as mean ROI 185 
intensity + 3 SD. For evaluation of evoked responses, the iGluu fluorescence was acquired at a 186 
frequency of 2.5 kHz from a rectangular ROI of 4 μm x 4 μm (20 x 20 pixels, binning 2) 187 
using a sCMOS camera (Andor Zyla4.2 plus) attached to a Zeiss wide field microscope 188 
(AxioObserver). In-house written software routines controlled the laser, camera and electrical 189 
stimulation of the axon/bouton. Each pixel of the ROI was evaluated separately for the 190 
construction of time- and space-dependent [Glu] profiles after release. The iGluu intensity 191 
values were expressed as supra-threshold pixel fluorescence 'F in % of the mean baseline 192 
fluorescence derived from the data points acquired during a 50 ms period prior to stimulation. 193 
The stimulus-induced changes of suprathreshold 'F/F in time or space are referred to as 194 
“iGluu transients” or simply “transients”. 195 
 196 
For the quantification of iGluu at single synapses we defined the following key parameters. 197 
The boundaries of the presynaptic bouton at rest (prior to any stimulation) were calculated 198 
from the F values at rest and included pixels with F larger ROI mean + 3 SD (see Fig. 1D, 199 
area outlined in blue). The area of suprathreshold pixels  at rest was approximated as a circle, 200 
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and the resulting virtual “Bouton diameter” was used as indicator of bouton size. The term 201 
“Peak amplitude” refers to the peak 'F/F value of an averaged intensity transient derived 202 
from all suprathreshold pixels (see Fig.1E, distance between dotted red lines). “Tau decay” 203 
abbreviated as“TauD” is the time constant of decay derived by fitting a monoexponential 204 
function to the decay from the peak of the averaged transients (see Fig.1E, amplitude between 205 
dotted red lines). The spatial extension of the iGluu signal is described on the basis of a virtual 206 
diameter derived from the area of all suprathreshold pixels combined to form a virtual circle. 207 
The respective diameter is referred to as “Spread”. The term “Peak spread” refers to the peak 208 
value of the averaged spread transient (see Fig. 1F, difference between dotted red lines).  The 209 
indicator “Residual 'F/F” is derived from fitting a double exponential function to the iGluu 210 
transient after the last stimulus. It corresponds to the 'F/F value at the intercept between the 211 
fast and slow phase of iGluu decay (see Fig. 2E, red horizontal line). “Integral 'F/F” refers to 212 
the sum of all responses during a series of 6 stimuli at 100 Hz within a period of 70 ms 213 
starting with the first stimulus. Dysfunctional synapses could best be detected by analysis of 214 
single pixel iGluu using the pixel with the highest iGluu elevation at any given terminal. The 215 
highest iGluu elevations were always found within or next to the bouton at rest. The peak 216 
amplitude of the single pixel transient with the highest iGluu elevation will be referred to as 217 
“Maximal amplitude” (see Fig. 4A-C, difference between red dotted lines). The respective 218 
TauD values are referred to as “TauDmax”.  In the following text, these parameter names will 219 
be written in italics and capitals to underline that these are pre-defined indicators introduced 220 
for the convenience of the present single synapse analysis.   221 
 222 
Single axon/bouton activation. To induce the Glu release from individual synaptic boutons 223 
under physiological conditions, a depolarizing current pulse was applied through an ACSF-224 
filled glass pipette (tip diameter <1 μM, resistance 10 MOhm) placed next to an axon in close 225 
proximity with a fluorescent varicosity. Responses were elicited at minimal intensity at a 226 
repetition frequency of 0.1 Hz. They disappeared when the pipette was moved by as little as 5 227 
pixel diameters (1 μm). Single bouton recording of iGluu in the presence of TTX was 228 
performed in elevated (5 mM) [Ca2+]ec using a biphasic stimulation. For more details on 229 
single bouton activation and recording of unitary EPSCs see (Kirischuk et al., 1999; 230 
Kirischuk et al., 2002) and (Dvorzhak et al., 2013a). 231 
 232 
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Patch-clamp recording of unitary EPSCs (uEPSCs). uEPSCs were recorded in the presence of 233 
bicuculline methiodide (BMI), as previously described (Dvorzhak et al., 2013b). Briefly, the 234 
intra-pipette solution contained (in mM): cesium methane sulfonate 100, CsCl 50, NaCl 5, 235 
CaCl2 0.5, EGTA 2.5, Hepes 25, MgATP 2, GTP 0.3 (pH 7.2). uEPSC were induced via 236 
optical activation of APs in hChR2(E123T/T159C)-EYFP expressing corticostriatal axons. 237 
Using the point illumination system UGA-42 of Rapp OptoElectronic, the duration and size of 238 
the laser pulse was adjusted to activate a synaptic response with distinct threshold. 239 
Stimulation was accepted as minimal if the following criteria were satisfied: (i) uEPSC 240 
latency remained stable (fluctuations <20% of means, (ii) lowering stimulus duration by 20% 241 
resulted in a complete failure of uEPSCs, (iii) an increase in stimulus duration by 20% neither 242 
changed mean amplitude nor shape of uEPSCs. To elicit AMPAR- and NMDAR-mediated 243 
components of uEPSCs, records were performed at holding potentials of −70 mV and +50 244 
mV, respectively.  245 
 246 
Synaptic EAAT2 immunofluorescence. Using deep isoflurane anesthesia, mice were 247 
transcardially perfused with ice-cold phosphate-buffered saline (PBS) followed by a solution 248 
of 4% (w/v) paraformaldehyde in PBS. Sagittal sections (30 μm) were prepared as previously 249 
described (Rothe et al., 2015). Freely floating sections were double-stained with guinea pig 250 
anti-vGluT1 (1:1000) and rabbit anti EAAT2 (1:2000), followed by respective secondary 251 
antibodies at a concentration of 1:800. Grey scale 16 bit images (1091x1091 pixels, pixel size 252 
0.073 μm, no binning) were acquired from the dorsal striatum using a Zeiss 100x oil 253 
immersion objective (NA1.3) and a Spot Insight camera system (Diagnostic Instruments Inc, 254 
Michigan, USA). All images were taken from the dorsal striatum. Areas of interest (AOIs, 255 
400x400 pixels, 853 μm2) were cropped from the larger viewfields, selecting neuropil areas 256 
with a minimum of cell somata or vessels. Quantification of EAAT2 immunofluorescence 257 
(IF) was performed using ImagePro Plus (MediaCybernetics, Roper, Sarasota, USA). Within 258 
the selected AOIs, smaller regions of interest (ROIs, 25 x 25 pixels, 3.33 μm2) were then 259 
centred to individual vGluT1+ spots to determine the level of synaptic EAAT2 IF. A 260 
threshold algorithm was used to define the boundaries of the EAAT2+ area excluding pixels 261 
with F<ROI mean +1.5 SD. The data is expressed as integral intensity of suprathreshold 262 
pixels.  The term “Synaptic integral EAAT2 IF” refers to the mean value from 10 individually 263 
assessed ROIs (i.e. the environment of 10 vGluT1+ terminals) within one AOI. The sections 264 
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from 3 WT and 3 Q175 HOM were stained together, and all images were acquired with the 265 
same camera settings. A total of 300 synapses were evaluated per genotype.  266 
 267 
Statistics. Data analysis was performed with Prism 8 (GraphPad, San Diego, USA). 268 
Considering that the comparison of the means could be influenced by inter-animal variance 269 
(Aarts et al., 2014) we have performed multi-level (“nested data”) analysis, where needed. P 270 
values of <0.05 were considered statistically significant. Significance levels were marked by 271 
asterisks, where * corresponds to P<0.05, ** - P<0.01 and *** - P<0.001. The numbers 272 
indicate animals, cells or presynaptic terminals, as mentioned in the figure legends or tables. 273 
Genotype-related effects are described in % of WT levels ('ofTabs. 2, 3) or as effect 274 
strength according to Cohen’s D or Hedges’ G.  D or G values larger 0.8 suggest that the 275 
respective effect was strong.  276 
 277 
RESULTS  278 
Evaluation of action potential-(AP-)mediated perisynaptic corticostriatal Glu transients 279 
using the new ultrafast sensor iGluu in acute slices from adult mice 280 
Placement of stimulating electrodes in the vicinity of corticostriatal terminals at rest was 281 
carried out under visual guidance (Fig. 1A). Bouton size was defined on the basis of resting 282 
fluorescence in the region of interest, ROI (Fig. 1, thick blue outline). The deduced virtual 283 
Bouton diameter exhibited a bimodal distribution (Fig. 1C). Varicosities with a diameter 284 
<=0.57 μm were defined as “Small” and, for the sake of brevity, tentatively referred to as IT 285 
type. Accordingly, varicosities with d >=0.63 μm were classified as “Large” or PT type. The 286 
size difference between terminals classified as Small (IT) vs. Large (PT) was significant at 287 
P<0.001 (Tab. 1). 288 
 289 
After electrical stimulation of a fluorescent corticostriatal axon in the dorsal striatum iGluu 290 
intensity increased in the pixels adjacent to the bouton at rest (Fig. 1D, thin black outline: 291 
active area). To assess the dynamic characteristics of the iGluu signal, the mean values of all 292 
supra-threshold pixel intensities ('F/F) generated by one synapse were plotted against time 293 
(Fig. 1E). The Peak amplitude was determined, and a monoexponential function (red line) 294 
was fitted to the averaged iGluu transient 'F/F to determine TauD. In the case of single pulse 295 
activation, there was no significant correlation between TauD and Bouton diameter (not 296 
illustrated).  297 
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 298 
The focus of the current experiments was placed on the time course of the iGluu signals. The 299 
position of the sensor and its low affinity for Glu naturally set limits to the detection of [Glu] 300 
elevations at larger distance from the site of vesicle exocytosis. Nevertheless, we also 301 
expected some preliminary information on the spatial characteristics of the iGluu signal. 302 
Therefore, the parameter Peak spread was deduced from the projection of the supra-threshold 303 
iGluu area to the focal plane and plotted against time (Fig. 1F, distance between dotted red 304 
lines).  Under condition of single pulse activation, Peak spread exhibited a significant 305 
positive correlation with TauD (Fig. 1G), but there were no terminal-type-related differences 306 
in the mean values of Peak amplitude, TauD and Peak spread after single pulse activation 307 
(Fig. 1H, Tab. 1).  308 
 309 
The contrasting properties of IT- and PT-type terminals became more obvious with repeated 310 
stimulation. Activation with stimulus pairs at an interval of 50 ms revealed differences in the 311 
paired pulse ratio (PPR) of Peak amplitude resulting in a positive correlation between PPR 312 
and Bouton diameter (Fig. 1I). This finding validated our size criterion for synapse 313 
identification and provided a first hint that IT and PT afferents may generate a differential 314 
load for Glu clearance when repeatedly activated.  315 
 316 
Frequency-dependent potentiation of Glu release at PT but not IT corticostriatal 317 
terminals 318 
As we aimed at exploring the limits of Glu release under conditions resembling the cortical 319 
activity during movement initiation, we applied 2 or 6 stimuli at frequencies of 20 or 100 Hz 320 
to elicit AP-mediated Glu release. At all frequencies tested, Small/IT and Large/PT terminals 321 
exhibited contrasting types of short-term plasticity, i.e. depression or no change in IT and 322 
potentiation in PT terminals (Fig. 2A-D and Tab.1). The Peak amplitude observed after the 323 
last stimulus in a train normalized to the response #1 were larger in PT than in IT terminals 324 
(Fig. 2E, Tab. 1). The normalized TauD values exhibited little difference (Fig. 2F), but the 325 
normalized Peak spread differed, being larger at PT-type varicosities (Fig. 2G). When tested 326 
at 100 Hz, PT synapses produced larger Integral 'F/F #1-6 than IT terminals (Fig. 2H) and 327 
accumulated more Residual 'F/F (Fig. 2I). The data suggests that the stimulus-locked 328 
response to the last AP adds to already incompletely cleared synaptic Glu. Thus, under 329 
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repetitive activation conditions,  corticostriatal afferents might be affected by conditions of 330 
weak astrocytic Glu uptake.  331 
 332 
Directly induced Glu transients in tetrodotoxin (TTX) 333 
With the AP mechanism intact, fluorescence might also originate from neighbouring release 334 
sites, especially if the axon heads deeper into the z-plane of the slice. In case of the serial (en 335 
passant) type synapses (as characteristic of PT afferents) this could erroneously increase 336 
signal duration and spread. Another caveat to be faced in the case of HD preparations is a 337 
possible alteration of voltage-activated channels in the cortical afferents (Silva et al., 2017) 338 
which may affect the duration of the presynaptic depolarization, the influx of Ca2+ and, 339 
consequently, the amplitude and duration of iGluu signals, without having a direct impact on 340 
the clearance machinery of the astrocytes. Moreover, respective deficits might preferentially 341 
occur in IT or PT axons. Considering these complexities it was decided to by-pass the AP 342 
mechanism by directly depolarizing the glutamatergic terminals in TTX and to focus, initially, 343 
on just one type of terminal. We selected the Large/PT input.  344 
 345 
To achieve in TTX [Glu] elevations similar to those obtained under physiological activation 346 
conditions from PT terminals at 100 Hz, it was sufficient to increase [Ca2+]ec to 5 mM and to 347 
add a hyperpolarizing prepulse to the standard 1ms depolarization used both in AP and TTX 348 
experiments. In the absence of a conditioning hyperpolarizing pre-pulse, the direct 349 
depolarization was insufficient to elicit release (Fig. 3A). The results of Fig. 3B, C indicate 350 
that the selected protocol provided a good match between the physiologically induced #6 351 
responses at 100 Hz and the directly induced responses in TTX. In any case, iGluu elevations 352 
were completely abolished by the Ca2+ channel blocker Cd2+ (Fig. 3D). This stimulation 353 
protocol was then expected to provide a reasonably standardized challenge of the synaptic 354 
Glu uptake in WT or HD mice. In the following experiments (Fig. 4 and 5) all synapses were 355 
tested in TTX applying paired ('t = 50 ms) biphasic pulses with a repetition frequency of 0.1 356 
Hz.  357 
 358 
Slowed Glu clearance at single PT-type corticostriatal terminals in HD 359 
In the Q175 mouse model of HD, motor symptoms (hypo- and dyskinesia, pathological 360 
circling) develop quite slowly. However, at the age of one year and older, both Q175 HET 361 
and HOM resemble the human phenotype at a symptomatic stage (Khakh et al., 2017). In 362 
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Q175 HOM motor impairment coincided with the appearance of pathological gamma 363 
oscillations in the local field potential (LFP) recordings at quiet rest (Rothe et al., 2015). In 364 
R6/2 mice, the changes in the LFP power spectrum were less pronounced after treatment with 365 
ceftriaxone (CEF), a transcriptional activator reported to increase the level of EAAT2 protein 366 
in the dorsal striatum (Miller et al., 2012). TFB-TBOA is a blocker of Glu uptake (Shimamoto 367 
et al., 2004). Its application would therefore simulate the effect of reduced EAAT2 368 
expression/activity in HD.  369 
 370 
Fig. 4A-C shows representative single synapse records from WT, HET and HOM. The black 371 
traces are individual pixel transients. The values between the dotted lines correspond to the 372 
Maximal amplitude. The white line is the mean transients derived from all suprathreshold 373 
pixels of a synapse. The monoexponential fitting curves are shown in grey (WT), red (HET) 374 
or magenta (HOM).  Fig. 4D presents the amplitude-scaled average responses for the three 375 
genotypes illustrating our main finding: In HD slices the iGluu transients decay more slowly 376 
than in WT (also see Movie 1).  Interestingly, this HD-related alteration was significant not 377 
only in Q175 HOM but also in HET (Fig. 4E) thereby demonstrating the usefulness of the 378 
Q175 HET model for research on astrocyte pathology in HD. 379 
 380 
An important additional question concerns the amount of released Glu. Is it increased by HD? 381 
- This was not the case, on the contrary. Despite a considerable variability in the Peak 382 
amplitude, we found a significant difference between WT and Q175 HET (Fig. 4F, Tab. 2). 383 
Unfortunately, multilevel data analysis failed to verify the difference between WT and HOM, 384 
due to the small number of available HOM. Our result is, however, in line with the data from 385 
R6/2 (Parievsky et al., 2017) suggesting that the presently disclosed HD-related prolongation 386 
of the iGluu signal occurs despite a concomitant decrease in the Glu output from single PT 387 
terminals.  388 
 389 
The above observations do not immediately prove that the prolongation of the iGluu transients 390 
in HD were due to altered functionality of the astrocytes. It was at least necessary to clarify 391 
whether TauD responded to pharmacological manipulation of astrocytic Glu transport. This 392 
was the case. The iGluu transients of PT terminals exhibited a clear sensitivity to TFB-TBOA 393 
(Fig. 4G). In WT, 100 nM of the antagonist prolonged the iGluu decay to the same extent as 394 
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the disease (Fig. 4I), the effect of pharmacological EAAT2 block being less pronounced in 395 
Q175 HOM (Fig. 4H, I).  396 
 397 
According to the presently available models of glutamatergic synapses (Zheng et al., 2008; 398 
Scimemi and Beato, 2009), a spread of >1.25 μm should be sufficient to activate 399 
extrasynaptic NMDA receptors. Although iGluu expression in the presynaptic terminals 400 
cannot provide exhaustive information on the spatial characteristics of perisynaptic [Glu], we 401 
nevertheless examined the Peak spread (black outlines in Fig. 4J).  Although there was a 402 
tendency for increase (Fig. 4K) this tendency failed to reach significance in Nested ANOVA 403 
(Fig. 4L) and nested t tests (Tab. 2). The mean spread velocity (about 1.5 μm/s) did not vary 404 
with the genotype (Fig. 4M).  405 
 406 
Positive correlation between Glu release and clearance in HD but not WT synapses 407 
Cumulative histograms and correlograms were plotted for further analysis of HD-related 408 
synapse pathology. The graphs of Fig. 5, except (D, E),  are based on the values obtained 409 
from 35 WT and 32 HET synapses, as explained by the evaluation scheme in (A). Each 410 
synapse is represented with 3 consecutive trials elicited at a frequency of 1/10 Hz. The 411 
interval between the stimuli for #1 and #2 was 50 ms. All data is from experiments in TTX. 412 
Fig. 5B, C shows the relative probability of occurrence of Peak amplitude and TauD, based on 413 
a total of 105 #1 responses from 35 WT synapses and 96 #1 responses from 32 HD synapses.   414 
 415 
Due to the highly variable configuration of the individual synapses with respect to the 416 
surrounding tissue and the focal plane of the camera, and due to inter-animal variation, the 417 
values obtained from the averaged iGluu trials of different synapses exhibited considerable 418 
variability. It was therefore necessary to normalize the data. Among several possibilities, we 419 
chose the #1 response of every trial to normalize the #2 responses. Typically #2 responses 420 
were smaller after larger #1 responses, and vice versa (Fig. 5A). The normalization reduced 421 
the impact of inter-synapse variability in favour of inter-trial variability. If in a given trial 422 
glutamate output touched the limits of uptake one could expect that such release event would 423 
produce a prolonged [Glu] transient. In contrast, if uptake capacity were sufficient for any 424 
amount of released glutamate, the fluctuating TauD values should be independent on Peak 425 
amplitude. It can be seen (Fig. 5D, E) that HD but not WT synapses displayed a positive 426 
correlation between TauD and Peak amplitude, consistent with the proposal that in HD some 427 
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synapse exhibited signs of clearance insufficiency, the prolongation of TauD being more 428 
pronounced in trials with enhanced Peak amplitude.  429 
 430 
Identification of dysfunctional synapses 431 
The pixels with the highest stimulus-induced elevations of 'F/F were always located within 432 
or immediately next to the boundaries of the resting terminal (see Fig. 1D). The Maximal 433 
amplitude derived from the highest single pixel transient can be regarded as a measure of the 434 
Glu output while TauDmax would reflect the clearance at the site of release minimizing the 435 
influence of Glu diffusion. Fig. 5F, G presents the cumulative probabilities of occurrence of 436 
Maximal amplitude and TauDmax. One can see that none of the HET entries of Maximal 437 
amplitude were larger 180%, and about 24% of TauDmax entries exceeded 15 ms. 40% of the 438 
tested synapses generated TauDmax in at least 1 of the 3 trials, and all of these responses 439 
were smaller than 180%. The differences in the ranges of these two indicators of release and 440 
clearance, respectively, are even more obvious in the correlograms of Fig. 5H, I. TauDmax 441 
values larger than 10 ms were (with 1 exception) absent in WT synapses tested with direct 442 
depolarization. As a first approximation, one can therefore state that, according to the 443 
distribution of TauDmax in WT and Q175 HET aged 15 to 19 months, 40% of HET synapses 444 
in the dosal striatum exhibited a pathological phenotype. Of course, this estimation is no more 445 
than an educated guess based on the assumptions that 15 ms is the largest TauDmax value to 446 
be expected in WT, and that in WT all synapses are fully functional. The data also hints that 447 
in dysfunctional synapses Glu may find its astrocytic transporter at bigger distance, in line 448 
with recent FRET data from corticostriatal synapses in R6/2 (Octeau et al., 2018). 449 
 450 
Reduced perisynaptic EAAT2 protein at corticostriatal terminals 451 
To clarify whether the observed clearance deficit is indeed accompanied by a reduction of 452 
EAAT2 protein levels in the environment of corticostriatal terminals, we performed a 453 
quantification of EAAT2 IF in fixed sections, as described in the Methods and illustrated in 454 
Fig. 6A-M.   455 
 456 
It has frequently been observed, and could possibly be noticed in the examples of Fig. 6A-D, 457 
that in 100x images from the dorsal striatum of HD mice the areas preferentially occupied by 458 
neuropil (i.e. areas without “holes” from the somata of neurons and astrocytes) are smaller 459 
than in WT. Moreover, a variable fraction of vGluT1+ varicosities seemed to be devoid of 460 
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synaptic EAAT2+ clusters, notably in HD (red boxes in Fig. 6D). Finally, due to the presence 461 
of capillaries and the attached astrocyte end-feet, there were EAAT2+ clusters without 462 
vGluT+ counterparts (arrows in Fig. 6B). To avoid ambiguity resulting from these 463 
complexities, it was decided to quantify synaptic EAAT2 IF individually in sufficiently small 464 
ROIs (1.825x1.825 μm2) centred to just one vGluT1+-positive terminal. Fig. 6E-L shows 465 
representative ROIs selected from larger AOIs in the dorsal striatum (Fig. 6B, D white boxes).  466 
A threshold algorithm was used to delineate the boundaries of the EAAT2 clusters from 467 
where the Synaptic integral EAAT2 IF values were actually sampled. Each data point in Fig. 468 
6N represents the mean value from 10 ROIs of 1AOI. vGluT1+ terminals without any 469 
suprathreshold EAAT2 were avoided which may have caused an underestimation of the actual 470 
difference. Nested data analysis showed that the synaptic integral EAAT2 IF was significantly 471 
lower in HD (Fig. 6N, Tab. 2). Cohen’s D (0.7878) suggests a strong HD-related effect (-472 
26%).  The histogram of synaptic integral EAAT2 intensity (Fig. 6O) illustrates the over-all 473 
shift towards lower values of Synaptic integral EAAT2 IF in individual ROIs.   474 
 475 
Prolonged NMDAR components of unitary EPSCs in HD 476 
NMDARs are sensitive indicators of [Glu] and therefore well suited to detect a potentially 477 
existing Glu clearance deficits in the environment of active synapses, provided that the 478 
analysed responses are derived from one or few synapses only (Chiu and Jahr, 2017). CEF is 479 
known to stimulate the transcription of SLC1A2, i.e. the gene encoding EAAT2. It is therefore 480 
used to verify a contribution of EAAT2 in a pathology or recovery effect. Functional benefits 481 
from CEF injections have already been reported (Miller et al., 2008; Miller et al., 2012) and 482 
were attributed to enhanced EAAT2 expression in astroglia. Here we used focal optical 483 
stimulation of individual channel rhodopsin-expressing corticostriatal axons to record 484 
uEPSCs at -70 and +50 mV. The experiments showed that the T50 value of the uEPSC 485 
recorded at +50 mV is i) solely dependent on NMDARs, ii) prolonged in HD and iii) 486 
recovered to WT levels after treatment with CEF suggesting a sensitivity of corticostriatal 487 
input to the level of EAAT2 expression (Fig. 7A-C, Tab. 3). Other parameters of 488 
corticostriatal uEPSCs were found unchanged by HD (Fig. 7D-F). However, more work is 489 
needed to actually prove that the observed potentiation of NMDAR activity in striatal 490 
projection neurons had been a result of wider spread of synaptically released glutamate.  491 
 492 
DISCUSSION  493 
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The analysis of single synapse iGluu transients in acute slice preparations from adult mice 494 
provides new information on Glu clearance in its relation to the respective transmitter load. 495 
To summarize: 1)  After single pulse activation, IT and PT synapses coped with the induced 496 
[Glu] elevations, but when challenged with high activation frequencies the [Glu] elevations 497 
produced by PT and IT terminals differed significantly (factor 2.6:1 for Integral 'F/F at 100 498 
Hz).  2) In HD, PT iGluu transients were found to decay more slowly. About 40% of HD 499 
synapses (14/32 in HET can be regarded as deficient, considering the time needed for 500 
complete Glu clearance in any trial (TauD of iGluu > 15 ms). 3) At any given terminal, the 501 
responses exhibited some inter-trial variability. Analysis of normalized #2 to #1 from 3 trials 502 
at the same synapse revealed that in Q175 HET, but not WT, iGluu transients with larger Peak 503 
amplitude were associated with larger TauD. This is evidence for a disease-related loss of 504 
independence between the indicators of uptake and release. 4) HD decreased the range of 505 
Maximal amplitude but increased the range of TauDmax. 5) Immunostaining suggests that the 506 
immediate environment of corticostriatal terminals contains less EAAT2 protein. 6) The 507 
NMDAR-mediated unitary EPSCs elicited by optical stimulation of single ChR-expressing 508 
corticostriatal axons were prolonged in Q175 HOM. 509 
 510 
PT versus IT terminals 511 
The unexpected differences in the properties of PT vs. IT terminals raise further questions on 512 
the mechanism(s) of release plasticity at the glutamatergic afferents to the dorsal striatum. 513 
Previous electrophysiological studies (Ding et al., 2008) implicated that corticostriatal 514 
connections preferentially exhibit paired pulse facilitation (PPF) while thalamostriatal 515 
connections are prone to paired pulse depression (PPD). Our results confirm preferential PPF 516 
with regard to the PT subgroup of corticostriatal afferents under physiological activation 517 
conditions (Tab. 1). However, as in any other synapse (for instance (Kirischuk et al., 2002)), a 518 
conversion from PPF to PPD is easily achieved by increasing the Ca2+ influx. There is a 519 
widely accepted rule of thumb suggesting that smaller initial responses are likely to produce 520 
facilitation, and vice versa. Considering that under the same experimental conditions PT and 521 
IT terminals produced about the same initial Glu output but opposite types of frequency-522 
dependent  plasticity, one can assume that these terminals indeed represent two classes of 523 
afferents with some differences in the presynaptic control of transmitter release.   524 
 525 
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Under condition of repetitive activation, the size of synaptic terminals and associated 526 
differences in the vesicle pool size could affect the integral Glu output, and also the degree of 527 
Glu escape (Genoud et al., 2006; Bernardinelli et al., 2014; Medvedev et al., 2014; Gavrilov 528 
et al., 2018). It has been hypothesized that thicker terminals could push the PAPs further away 529 
from the site of exocytosis which may result in wider signal spread if the transporters are 530 
challenged with a pronounced build-up of [Glu], as found in PT terminals.  531 
 532 
The hypothesis of non-saturating Glu uptake in healthy glutamatergic synapses 533 
In view of a long history of changing opinions on the significance of astrocytic Glu transport 534 
as a possible determinant of synaptic strength it is good to have new tools at hand to shed 535 
light on the possible limits of Glu clearance in health and disease. Our uEPSC data from 536 
synaptic connections with one or few terminals confirm the long-standing idea that a 537 
weakness of Glu uptake has little influence on the decay kinetics of the fast desensitizing 538 
AMPA responses (Hestrin et al., 1990; Asztely et al., 1997; Goubard et al., 2011; Campbell et 539 
al., 2014). Moreover, our iGluu data from healthy mice are in line with the more controversial 540 
prediction that in “normal” glutamatergic synapses glutamate transport would cope with any 541 
amount of physiologically released Glu (Diamond and Jahr, 2000; Tzingounis and Wadiche, 542 
2007). Nevertheless, the present iGluu-based postulate of non-saturating Glu uptake for IT- 543 
and PT-type corticostriatal synapses will need further verification under a wider range of 544 
conditions.  It was already shown that the state of astrocytes could affect the structural 545 
plasticity of PAPs  (Theodosis et al., 2008; Reichenbach et al., 2010; Bernardinelli et al., 546 
2014; Heller and Rusakov, 2015; Verkhratsky and Nedergaard, 2018). Activity- and disease-547 
dependent PAP retraction could produce a large variety of spill-out and spill-in effects which 548 
may not only change the access of the available transmitter(s) to respective neuronal and glial 549 
receptors, but also influence the efficacy of the astrocytic transport machinery itself 550 
(Armbruster et al., 2016).  551 
 552 
Evidence for impairment of Glu clearance in HD 553 
Symptomatic HD is characterized by the loss of glutamatergic terminals in the dorsal striatum 554 
but it is still not clear whether this disease-related process of synapse pruning is to be 555 
attributed to glutamate excitotoxicity (Reiner and Deng, 2018). While the long-term 556 
consequences of reduced Glu clearance remain to be clarified, our present experiments 557 
provide new evidence suggesting that in symptomatic Q175 mice a significant fraction of PT 558 
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(~40%) synapses is afflicted by the disease, most likely exhibiting alterations in both uptake 559 
and release. When analysing the normalized Peak amplitude in 3 consecutive trials of the 560 
same synapse, it turned out that HD but not WT synapses displayed a positive, presumably 561 
pathological correlation between Peak amplitude and TauD. Considering in addition that i) 562 
treatment of WT with TBOA produced  TauD values similar to those in HD, and ii) Synaptic 563 
integral EAAT2 IF was significantly less in HD, it is suggested that glutamate uptake, in 564 
general, and astrocytic EAAT2 deficiency, in particular, contribute to the observed synaptic 565 
dysfunction in HD.  566 
 567 
However, this conclusion is not shared by all researchers. First of all, there is some evidence 568 
that EAAT2 is also localized on presynaptic terminals (Petr et al., 2013). In the R6/2 model of 569 
HD, the Rosenberg group confirmed the reduced expression of EAAT2 and the beneficial 570 
effects of CEF. But experiments with partial knock-down of SLC1A2 revealed little change in 571 
the fraction of EAAT+ terminals and, even more important, in the progression of HD. Based 572 
on these and other findings, Rosenberg and colleagues questioned a role of EAAT2 in the 573 
pathogenesis of HD and forwarded the intriguing hypothesis that the observed down-574 
regulation of EAAT2 applies to a nonfunctional intracellular fraction of the EAAT2 protein. 575 
We find the reported 40% reduction of the glutamate uptake activity in synaptosomes after 576 
conditional GLT1 knock-out (Petr et al., 2015) somewhat surprising considering that in the 577 
present material no more than 5% of the terminals exhibited full co-localization of vGluT1 578 
and EAAT2 IF.   579 
 580 
Considering the novelty of our present approach, it is not so unexpected that some results 581 
from other labs were not confirmed, in particular those obtained with the slow Glu indicator 582 
iGluSNFR (Marvin et al., 2013). (Parsons et al., 2016) activated glutamate release by high-583 
frequency electrical field stimulation and used the iGluSnFR sensor to record Glu elevations 584 
in large viewfields. They found no HD-related difference in the fluorescence decay, in 585 
contrast to (Jiang et al., 2016).  Both studies were carried out in R6/2 mice, the main 586 
difference being the site of expression of the Glu sensor (neurons vs. astrocytes). (Parievsky 587 
et al., 2017) applied optical field stimulation of channel-rhodopsin-(ChR2(H134R))-588 
expressing corticostriatal axons to induce EPSCs in SPNs. This approach showed no increase 589 
in the decay times (T90-10) of NMDAR-mediated currents. On the contrary, the latter were 590 
significantly shorter in HD. However, considering the mean T90-10 values of this study (~750 591 
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ms) it seems possible that the asynchrony of release characteristic produced by this type of 592 
optical field stimulation may not give the resolution needed for the estimation of synaptic Glu 593 
clearance. In general, space- and volume-averaging effects resulting from bulk activation of 594 
synaptic and non-synaptic Glu release and low resolution of the electrical or fluorescent 595 
signals can be expected to influence the interpretation of results on Glu uptake and release 596 
(see (Jensen et al., 2017; Reynolds et al., 2018) for a concise summary on these issues).  597 
 598 
A question receiving growing attention in the field of synaptic plasticity and dysfunction is 599 
the role of other glutamate uptake mechanisms. Scimemi and colleagues (Bellini et al., 2018) 600 
illuminated the role of Glu uptake from two sides - pathology and functional rescue. Their 601 
convincing evidence suggests that the neuronal Glu transporter EAAT3 (EAAC1) ensures 602 
long-term synaptic activity by reducing the activation of mGluR1 in the striatum.   603 
 604 
The ultimate proof of Glu uptake deficiency as a cause of synapse pathology in the dorsal 605 
striatum will be the recovery of normal synaptic performance after a therapeutic intervention 606 
targeting the astrocytes. Most intriguing, intrastriatal injection of a recombinant viral Kir4.1 607 
vector restored a normal level of EAAT2 protein (Tong et al., 2014). However, it is not yet 608 
clear whether a mere stimulation of EAAT2 expression would suffice to achieve the desired 609 
reversal of motor symptoms in HD, because synaptic targeting and the activity of Glu 610 
transporters are also influenced by local translation (Sakers et al., 2017), lateral mobility 611 
(Murphy-Royal et al., 2015) and internalization (Leinenweber et al., 2011; Ibanez et al., 612 
2016). Clearly, much more information is needed to understand the regulation of Glu uptake 613 
in the context of other astrocytic signaling cascades. 614 
  615 
FIGURE LEGENDS 616 
Fig. 1. Monitoring single synapse Glu transients in acute slices from adult mice after 617 
expression of the genetically encoded ultrafast Glu sensor iGluu in corticostriatal neurons. (A) 618 
Resting iGluu fluorescence merged to the respective 63x DIC image of a corticostriatal slice 619 
showing an axon with 3 adjacent varicosities and a stimulation pipette at the central bouton. 620 
(B) Simplified scheme of the corticostriatal circuitry (Reiner et al., 2010), illustrating the 621 
concept of preferential projection of pyramidal tract (PT) neurons to indirect pathway striatal 622 
projection neurons (iSPNs) and intratelencephalic (IT) neurons to direct pathway SPNs 623 
(dSPNs), with size-differences between the IT and PT terminals. (C) Bimodal distribution of 624 
20 
 
 
 
 
20 
bouton diameters as determined by the supra-threshold resting fluorescence before 625 
stimulation. Boutons with diameter >= 0.63 μm were defined as “Large” and assumed to be 626 
issued by PT axons. (D) Example of a type PT bouton with the respective iGluu fluorescence 627 
at rest (left) and at the peak of an AP-mediated iGluu response (right). (E, F) iGluu responses 628 
recorded from the bouton shown in (A, D). Experiment in 2 mM Ca2+ and 1 mM Mg2+. (E) 629 
Simultaneous recording of stimulation current (upper trace) and mean intensity of supra-630 
threshold pixels (bottom trace). Peak amplitude (between dotted red horizontal lines) and a 631 
monoexponential function fitted to the decay from this peak (red overlay). TauD values next 632 
to the fitting curves. (F) Plot of spread against time (for a definition see Methods). Peak 633 
spread: difference between dotted red horizontal lines. (G) Positive correlation between peak 634 
spread and TauD after stimulus #1. (H) Peak amplitude of responses to stimulus #1. There is 635 
no difference between small and large terminals. (I) Significant correlation between the PPR 636 
of peak amplitude and bouton diameter. * - P<0.05 , ** - P<0.01, *** - P<0.001.   637 
 638 
Fig. 2. Contrasting dynamics of Glu release from small and large corticostriatal terminals. (A-639 
D) Specimen records of AP-mediated iGluu signals from small and large boutons, as obtained 640 
with 20 and 100 Hz stimulation. All iGluu transients were elicited in an AP-dependent manner 641 
in 2 mM Ca2+. Experimental conditions as in Fig. 1. The large terminals produced a 642 
significant build-up of residual iGluu (single arrow), i.e. fluorescence added to the fast 643 
stimulus-locked transients after #6 (double arrow). (E-I) Quantification of results. Note that 644 
the time integral of all supra-threshold pixel intensities generated by a 6-pulse train at 100 Hz 645 
during a sampling period of 70 ms was much bigger in large boutons (H). 3-way ANOVA 646 
statistics: (E) Leven's test F(df1=29, df2=29) = 3.802, P<0.001. Small vs. Large F(1,29) = 647 
19.507, P<0.001. Frequency F(1,29) = 7.207, P = 0.012. Animal F(9,29) = 0.765, P = 0.649. 648 
Animal-Frequency F(8,29) = 1.154, P = 0.359.  Animal-Small/Large F(5,29) = 0.46, P = 649 
0.803. Small/Large-Frequency F(1,29)=0.000, P = 0.999. (F)  Leven's test F(df1=29, df2=29) 650 
= 2.202, P = 0.020. Small vs. Large F(1,29) = 1.207, P = 0.281. Frequency F(1,29) = 1.038, P 651 
= 0.317. Animal F(9,29) = 4.330, P = 0.002. Animal-Frequency F(8,29) = 2.398, P = 0.041. 652 
Animal-Small/Large F(5,29) = 2.206, P = 0.82. Small/Large-Frequency F(1,29) = 0.305, P = 653 
0.585. (G) Leven's test F(df1=29, df2=29) = 3.202, P = 0.015. Small vs. Large F(1,29) = 654 
11.226, P = 0.002. Frequency F(1,29) = 21.526, P<0.001. Animal F(9,29) = 0.840, P = 0.575. 655 
Animal-Frequency F(8,29) = 0.895, P = 0.533. Animal-Small/Large F(5,29) = 0.818, P = 656 
0.547. Small/Large-Frequency F(1,29) = 0.155, P = 0.696. (H) Nested t test: F(1,12) = 6.05. P 657 
21 
 
 
 
 
21 
= 0.032. (I) Nested t test: F(1,25) = 6.47, P = 0.018. Hedges’G values: (E) Small vs. Large at 658 
20 Hz: D = 2.4, Small vs. Large at 100 Hz: D = 1.3. F) G<0.4 in all pairs. (G) Small vs. Large 659 
at 20 Hz: D = 1.4, Small vs. Large at 100 Hz: D = 1.1. H D = 0.8. (I) G = 1.0.  (H) G=1.0. The 660 
asterisks on the horizontal bars on the graphs denote significance levels according to the 661 
nested t test.  * - P<0.05 , ** - P<0.01, *** - P<0.001.   662 
 663 
Fig. 3. Responses to directly induced test pulses by-passing the AP mechanism in WT 664 
boutons of type PT.  (A) Experiment in elevated [Ca2+]ec. Left: Response to electrical 665 
stimulation in the absence of TTX elicited by a short (1 ms) depolarizing pulse. In 5 mM Ca2+ 666 
the AP-mediated response exhibits paired pulse depression. Middle: same condition but in the 667 
presence of TTX. Note complete block of Glu release. Right: Response in 5 mM Ca2+ and 668 
TTX, but elicited with the 1 ms depolarizing pulse preceded by a short hyperpolarizing pulse. 669 
This configuration will in the following be referred to as "Ca 5 - Direct". (B, C) Stimulus 670 
intensity for direct activation of Glu release in TTX ("Ca5 - Dir") was adjusted such that the 671 
peak amplitude and peak spread of iGluu signals matched the amplitudes observed with the 672 
last (#6) 100 Hz response under physiological conditions ("Ca 2 - AP"). (D) The directly 673 
induced responses were completely blocked by Cd2+ (500 μM). Cohen's D:  CTRL vs. Cd = 674 
4.4, Cd vs.Wash = 2, CTRL vs. Wash = 2.3. * - P<0.05 , ** - P<0.01, *** - P<0.001.  675 
 676 
Fig. 4. HD-related differences in the clearance of synaptically released Glu. (A-C) 677 
Superposition of suprathreshold pixel transients induced by direct activation of PT-type 678 
varicosities in the the presence of TTX. Differences between dotted red horizontal lines: 679 
Maximal amplitude of a single pixel transient. In white: averaged transient from all 680 
suprathreshold pixels. Curve in grey (WT), red (HET) and magenta (HOM) - 681 
monoexponential function fitted to the decay from peak amplitude.  (D) Averaged responses 682 
normalized to same peak amplitude, same boutons as in (A-C). The respective fitting curves 683 
highlight the differences in the duration of the Glu transients. (E, F) Quantification of results 684 
from the entire data set. WT -gray, HET - red and HOM -magenta. (G) Incubation of WT 685 
slices in 100 nM of TFB-TBOA simulated the depression of Glu clearance observed in HOM 686 
(H, I) (J-L) Specimen images, traces and quantification for the spread in WT and HD mice. 687 
(M) Lack of genotype-related differences in spread velocity. Nested ANOVA statistics: (E) 688 
F(2,26) = 4.17, P = 0.027. (F) F(2,26) = 2.7, P = 0.086. (I) F(3,15) = 5.5, P = 0.0095. (L) 689 
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F(2,26) = 0.52, P = 0.600. (M) F(2,26) = 0.65, P = 0.528. * - P<0.05 , ** - P<0.01, *** - 690 
P<0.001. See Tab. 2 for more details. 691 
 692 
Fig. 5. Relationship between Glu release and uptake and identification of dysfunctional 693 
synapses in HD. (A) Basal scheme of data organization. The graphs of (B-I) are based on 3 694 
consecutive trials from each synapse. Data from 35 PT-type WT synapses and 32 HET 695 
synapses, except (D, E). (B, C) Cumulative histograms of #1 Peak amplitude and #1 TauD 696 
values. (D, E) Plots of normalized (to #1of the first trial) #2 responses. Data from 31 PT-type 697 
WT synapses and 30 HET synapses. Note that HET but not WT exhibited a positive 698 
correlation between TauD and Peak amplitude. In (E) the slope parameters of the three 699 
predictors Peak amplitude, Trial and Animal were significant for Peak amplitude (P= 0.015) 700 
and Animal (P=0.002). The latter suggests that in different Q175 HET the disease has 701 
progressed to different degree. Significance levels for other variables: Peak amp*Animal -702 
P=0.003, Peak amp*Trial - n.s., Trial*Animal - n.s. (F, G) Cumulative histograms of #1 703 
Maximal amplitude and #1 TauDmax. In the HET sample all Maximal amplitude values were 704 
<= 180%. In the WT sample all TauDmax values were <=15 ms. A total of 40 synapses 705 
exhibited in at least 1 of the 3 trials a TauDmax value exceeding the Threshold defined by the 706 
longest TauDmax in WT. 24% of the HET trials exceeded the 15 ms limit. Accordingly 30% 707 
of the WT responses were larger than in HET, and these suprathreshold responses were 708 
derived from 51% of the synapses. (H, I) Correlograms of TauDmax and Maximal amplitude 709 
for WT and Q175 HET. These graphs emphasize the HD-related differences in the ranges of 710 
Maximal amplitude and TauDmax. Maximal amplitude values exclusively seen in WT are 711 
shown in grey, and TauDmax values exclusively encountered in HET are shown in red. * - 712 
P<0.05 , ** - P<0.01, *** - P<0.001. 713 
 714 
Fig. 6. HD-related reduction of synaptic EAAT2 immunofluorescence (IF).  Data from 3 male 715 
Q175 HOM (CAG range 176-191, age range 49-54 weeks) and 3 male WT siblings.  (A, C) 716 
Areas of interest (AOIs) cropped from larger view fields for quantification of synaptic 717 
integral EAAT2 IF.  Numbers on EAAT2 image: mean AOI IF intensity (no intensity 718 
threshold, same display range for WT and HOM). (B, D) Overlay of vGluT1 and EAAT2 719 
images (display ranges optimized for object recognition). Squares outlined in white show 720 
ROIs as used for estimation of synaptic integral EAAT2 IF. Both WT and HOM images 721 
contain numerous EAAT2 clusters without synaptic terminals, presumably representing 722 
23 
 
 
 
 
23 
astrocytic end-feet in contact with blood vessels, see arrows  in (B). In HD vGluT1 723 
varicosities may occur without EAAT2 clusters (ROIs boxed in red). (E-H) and (I-L) enlarged 724 
ROIs showing (in this order) vGluT1, EAAT2, overlay and the suprathreshold EAAT2 as 725 
used for estimation of integral EAAT2 IF in the immediate vicinity of one corticostriatal 726 
vGluT+ terminals. Numbers on ROIs: integral suprathreshold fluorescence intensity for the 727 
EAAT2 channel. (M) Histogram of AOI EAAT2 pixel intensity. Note that “holes” from 728 
somata and blood vessels would influence the mean AOI values of EAAT2 intensity. (N) 729 
Small ROI quantification of synaptic integral EAAT2 intensity by nested data analysis. Each 730 
data point represents the mean from 10 rectangular ROIs within one AOI. Dotted lines 731 
indicate mean level from 3 animals (with a total of 30 AOIs, 300 synapses) per genotype. 732 
Numbers on column: AOIs and animals (in brackets), same for all columns. Statistics (F, 733 
DFn, DFd): 9.403, 1, 58. P = 0.0033. (O) Histogram of synaptic integral EAAT2 from WT 734 
and Q175 HOM.  n=300 per group. Effect size (Cohen's D) was obtained with the t value 735 
calculated by the nested t test. Symbols, abbreviations: # animal number, a.u. arbitrary units. 736 
Color code: WT  - light grey, HOM  - magenta. * - P<0.05 , ** - P<0.01, *** - P<0.001.    737 
 738 
Fig. 7. HD-related prolongation of the NMDAR component in uEPSCs elicited by optical 739 
stimulation of single corticostriatal afferents visualized by EYFP fluorescence after the 740 
expression of CaMKIIa.hChR2(E123T/T159C)-EYFP.hGH. (A) Specimen traces as recorded 741 
at two different holding potentials in the presence of bicuculline methiodide (25 μM). (B) 742 
Same traces as (A) but aligned to peak. See prolonged decay in contrast to records at -70 mV. 743 
The half-decay time of the uEPSC (T50) was sensitive to APV (not illustrated). Treatment 744 
with CEF shortened the uEPSC at +50 mV to WT level (blue traces). (C-F) Quantification of 745 
results. Note significantly larger T50 values of the NMDAR-mediated response at +50 mV 746 
and recovery after CEF treatment (C). Numbers in columns: number of tested SPNs and 747 
animals (in brackets). For detailed results of nested data analysis and Hedges'  G see Tab. 3. * 748 
- P<0.05 , ** - P<0.01, *** - P<0.001.   749 
MOVIE LEGEND 750 
Movie 1 Still. Movie 1 Still. Slow motion video, factor 1240x.Upper row: Images from WT 751 
(left), Q175 HET (middle) and HOM (right). Lower row: Respective averaged IGluu 752 
transients from all suprathreshold pixels.  753 
 754 
TABLE LEGENDS 755 
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Tab. 1. Comparison of iGluu signals in varicosities type ”Small“ (presumably IT) and “Large” 756 
(presumably PT). Peak amp – Peak amplitude: 'F/F at the peak of averaged transient derived 757 
from all suprathreshold  pixels.  TauD – time constant of decay derived from fitting a 758 
monoexponential function to the decay from peak amplitude. Peak spread – peak of the 759 
spread transient. See Methods section for more details. N-t – number of terminals. N-a – 760 
number of animals. '(%) – difference to WT in % of  WT (=100%). In bold: indicators with 761 
significant afferent-related difference according to multi-level analysis (terminals nested in 762 
animals). 763 
 764 
Tab.  2. Comparison of WT with Q175 HET or HOM. Peak amp – peak amplitude: 'F/F at 765 
the peak of averaged transient derived from all suprathreshold pixels.  TauD – time constant 766 
of decay derived from fitting a monoexponential function to the decay from peak amplitude. 767 
Peak spread – peak of the spread transient. See Methods section for more details. N-t – 768 
number of terminals. N-a – number of animals. '(%) – difference to WT in % of  WT 769 
(=100%). *Each data point represents the mean value from 10 synapses within one area of 770 
interest. In bold: indicators with significant afferent-related difference according to multi-771 
level analysis (level 1: animals, level 2: terminals). 772 
 773 
Tab.  3. Comparison of uEPSCs in WT, Q175 HOM and Q175 HOM treated with ceftriaxone 774 
(CEF). *Amplitude without failures. N – number of cells (c) or animals (a). MC – multiple 775 
comparison test according to Benjamini, Krieger, Yekutieli. '(%) - % change in comparison 776 
with WT (=100%). Note that the effect of genotype on TauD is both significant and strong 777 
(bold row). 778 
 779 
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iGluu signals at IT vs. PT terminals 
Varicosities type "Small" Varicosities type "Large" Statistics (nested t test) 
Mean SE N-t N-a Mean SE N-t N-a F (DFn,Dfd) P Hedge’s G 
Bouton diameter (μm) 0.51 0.01 12 6 0.74 0.02 20 3 77.00 (1,14) <0.001 4.018 
Peak amp #1 (%) 22.72 3.22 12 6 35.97 6.02 20 10 2.30 (1,14) 0.152 0.590 
TauD #1 (ms) 4.65 0.75 12 6 4.56 0.39 20 10 0.01 (1,30) 0.906 0.044 
Peak spread #1 (μm) 1.54 0.19 12 6 1.24 0.11 20 10 1.76 (1,14) 0.206 0.518 
First/last ratio peak amp, 20 Hz 0.68 0.06 12 6 1.18 0.05 20 10 37.50 (1,14) <0.001 2.382 
First/last ratio peak amp, 100 Hz 0.98 0.09 10 6 1.61 0.14 17 9 10.1 (1,25) 0.004 1.269 
First/last ratio peak spread, 20 Hz 0.74 0.04 12 6 1.02 0.05 20 10 11.9 (1,14) 0.004 1.367 
First/last ratio peak spread, 100 Hz 1.13 0.1 10 6 1.5 0.08 17 9 7.58 (1,25) 0.011 1.097 
Integral 'F/F #1-6, 100 Hz 0.89 0.14 10 6 2.28 0.51 17 9 6.05 (1,12) 0.032 0.828 
Residual 'F/F amp after #6/peak amp #1, 100 Hz  0.38 0.1 10 6 0.77 0.1 17 9 6.47 (1,25) 0.018 1.013 
Residual 'F/F spread after #6, 100 Hz (μm) 1.05 0.15 10 6 1.66 0.15 17 9 5.21 (1,12) 0.042 1.071 
 
  
Tab. 1. Comparison of iGluu signals in varicosities type ”Small“ (presumably IT) and “Large” (presumably PT). Peak amp – 
Peak amplitude: 'F/F at the peak of averaged transient derived from all suprathreshold  pixels.  TauD – time constant of decay 
derived from fitting a monoexponential function to the decay from peak amplitude. Peak spread – peak of the spread transient. See 
Methods section for more details. N-t – number of terminals. N-a – number of animals. '(%) – difference to WT in % of  WT 
(=100%). In bold: indicators with significant afferent-related difference according to multi-level analysis (terminals nested in 
animals). 
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Directly induced iGluu 
transients at PT terminals 
WT HET HOM 
Mean SE N-t N-a Mean SE N-t N-a ' Mean SE N-t N-a ' 
Varicosity diameter (μm) 0.77 0.01 35 10 0.76 0.01 32 16 ns 0.72 0.01 20 3 ns 
Peak amp  (%) 80.26 8.59 35 10 28.93 2.36 32 16 -64      
TauD  (ms) 3.39 0.41 35 10 11.28 2.14 32 16 233 14.27 3.60 20 3 321 
Peak spread (μm) 1.28 0.06 35 10 1.55 0.09 32 16 ns 1.59 0.13 20 3 ns 
Synaptic EAAT2 IF at vGluT2 
terminals 
 
Synaptic integral EAAT2 IF  (a.u.) 356.3 25.12 30* 3      263.1 17.5 30* 3 -26 
 
 
 
 
 
 
Tab.  2. Comparison of WT with Q175 HET or HOM. Peak amp – peak amplitude: 'F/F at the peak of averaged transient 
derived from all suprathreshold pixels.  TauD – time constant of decay derived from fitting a monoexponential function to the 
decay from peak amplitude. Peak spread – peak of the spread transient. See Methods section for more details. N-t – number of 
terminals. N-a – number of animals. '(%) – difference to WT in % of  WT (=100%). *Each data point represents the mean value 
from 10 synapses within one area of interest. In bold: indicators with significant afferent-related difference according to multi-
level analysis 
(level 1: 
animals, level 2: 
terminals). 
 
 
 
 
 
 
 
 
 
 
Genotype effect 
(nested t test) 
WT-HET WT-HOM 
F (DFn,Dfd) P Hedges’ G F  (DFn,Dfd) P Hedges’ G 
Varicosity diameter (μm) 0.005 (1,24) 0.943 0.046 1.542 (1, 11) 0.240 0.046 
Peak amp (%) 4.690 (1, 24) 0.040 1.355    
TauD (ms) 5.690 (1, 24) 0.025 0.922 9.151 (1, 11) 0.012 1.105 
Peak spread (μm) 1.489 (1, 24) 0.234 0.618 0.2539 (1, 11) 0.624 0.665 
Synaptic integral EAAT2 IF (a.u.) 
2
   9.403 (1, 58) 0.003 0.788 
P values/Tests for 
comparison of genotypes
Tested genotype pairs with nested t- Ghedges 
WT-HET WT-HOM HET- WT- WT- HET-
Varicosity diameter (μm) 0.943 0.240 0.158 0.046 0.046 0.516 
  1 
 
Corticostriatal unitary EPSCs 
WT  HOM HOM+CEF Nested MC Nested ANOVA  
Mean SE 
N 
Mean SE 
N '
% 
Mean SE 
N '
 
WT 
/HOM 
HOM 
/CEF 
F/P/Hedges’ G 
c a c a c a 
Amp* NMDAR resp at +50 mV (pA) 16.03 1.79 24 6 21.97 1.83 20 4 - 13.85 2.32 11 3 - 0.3202 0.1742 1.15/0.3533/0.700 
T50 of NMDAR  resp at +50 mV (ms) 20.68 1.95 24 6 35.74 3.71 20 4 73 21.25 2.63 11 3 - 0.0124 0.0117 4.67/0.0340/1.141 
Amp* of AMPAR resp at -70 mV (pA) 29.07 2.82 27 6 38.71 2.54 27 5 - 30.05 3.03 26 5 - 0.1314 0.1016 1.65/0.2100/0.691 
TauD AMPAR resp  at -70 mV (ms) 4.06 0.24 27 6 4.76 0.31 27 5 - 4.05 0.29 26 5 - 0.1417 0.1111 1.84/0.1767/0.486 
CV of AMPAR resp at -70 mV (pA) 42.55 3.78 27 6 31.21 2.80 27 5 - 37.78 2.79 26 5 - 0.1106 0.5351 1.35/0.2742/0.656 
Failure rate AMPAR resp  at -70 mV (ms) 8.14 1.51 27 6 4.91 1.01 27 5 - 6.37 1.29 26 5 - 0.1073 0.4196 1.51/0.2408/0.484 
 
Tab.  3. Comparison of uEPSCs in WT, Q175 HOM and Q175 HOM treated with ceftriaxone (CEF). *Amplitude without failures. 
N – number of cells (c) or animals (a). MC – multiple comparison test according to Benjamini, Krieger, Yekutieli. '(%) - % change in 
comparison with WT (=100%). Note that the effect of genotype on TauD is both significant and strong (bold row). 
 
 
 
 
